Signature Diagnostics Receives Extended Patent Protection for its Proteasome-Complex Inhibitors
Signature Diagnostics AG announced that the European Patent Office (EPO) has granted a new patent providing extended protection for drug molecules licensed by the company from the Technical University of Darmstadt. The new patent (EP 1858913) covers peptide-mimetics and their use as inhibitors of the human proteasome complex. The molecules have immediate application in a variety of indications, including cancer and inflammatory disease. The company is currently seeking cooperation partners for further development of these proteasome-inhibitor drug candidates.
"This patent further strengthens our strong intellectual property portfolio in key therapeutic areas such as cancer and inflammation," commented André Rosenthal, Chief Executive Officer of Signature Diagnostics. "We are committed to maximizing the patent protection for these drug candidates, as they are essential value-drivers for the company and its future partners."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.